Onconetix, Inc.ONCOEarnings & Financial Report
Onconetix, Inc. is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for underserved cancer patients. Its pipeline includes candidates for hard-to-treat solid tumors, operating mainly across North American and global oncology markets, prioritizing treatments with superior safety and efficacy over existing standard care options.
ONCO Q4 FY2025 Key Financial Metrics
Revenue
$303.6K
Gross Profit
$247.7K
Operating Profit
$-1.3M
Net Profit
$5.7M
Gross Margin
81.6%
Operating Margin
-422.1%
Net Margin
1867.5%
YoY Growth
-57.4%
EPS
$-5.02
Onconetix, Inc. Q4 FY2025 Financial Summary
Onconetix, Inc. reported revenue of $303.6K (down 57.4% YoY) for Q4 FY2025, with a net profit of $5.7M (up 119.3% YoY) (1867.5% margin). Cost of goods sold was $55.9K, operating expenses totaled $1.5M.
Key Financial Metrics
| Total Revenue | $303.6K |
|---|---|
| Net Profit | $5.7M |
| Gross Margin | 81.6% |
| Operating Margin | -422.1% |
| Report Period | Q4 FY2025 |
Onconetix, Inc. Annual Revenue by Year
Onconetix, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $815.4K).
Onconetix, Inc. Quarterly Revenue & Net Profit History
Onconetix, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $303.6K | -57.4% | $5.7M | 1867.5% |
| Q3 FY2025 | $303.7K | -25.4% | $-8.8M | -2892.7% |
| Q2 FY2025 | $106.5K | -84.9% | $-2.4M | -2227.8% |
| Q1 FY2025 | $101.6K | -85.5% | $-8.5M | -8408.8% |
| Q4 FY2024 | $712.0K | — | $-29.4M | -4134.7% |
| Q3 FY2024 | $406.9K | — | $-3.8M | -940.7% |
| Q2 FY2024 | $704.8K | — | $-14.3M | -2029.8% |
| Q1 FY2024 | $700.4K | — | $-11.1M | -1587.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $700433 | $704848 | $406859 | $711976 | $101630 | $106494 | $303651 | $303596 |
| YoY Growth | N/A | N/A | N/A | N/A | -85.5% | -84.9% | -25.4% | -57.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $75.0M | $59.5M | $61.9M | $28.2M | $18.8M | $19.1M | $19.7M | $24.9M |
| Liabilities | $25.3M | $24.0M | $20.9M | $18.6M | $14.3M | $12.8M | $16.3M | $9.2M |
| Equity | $-21.5M | $-35.8M | $33.9M | $8.5M | $4.0M | $5.9M | $3.4M | $15.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.2M | $-3.2M | $-1.1M | $-917647 | $-2.0M | $-1.4M | $-3.2M | $-3.1M |